Drug Combination Details
| General Information of the Combination (ID: C83784) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Sorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
|
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | EIF4EBP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GSK-3B | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | S6K1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BECN1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BRAF | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | c-RAF | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MEK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MEK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PTEN | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ULK1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | KG-1 | CVCL_0374 | Adult acute myeloid leukemia | Homo sapiens | ||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
The combination effect of ATO and sorafenib in AML cell lines is apoptotic and autophagy. | |||||
| Experiment 3 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | c-RAF | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MEK1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
A synergistic effect is observed between the sorafenib and As2O3 in their inhibition of HepG2 cell proliferation, the mechanisms of which may involve reduction of mitochondrial transmembrane potential and Raf/MEK/ERK pathway inhibition. | |||||
| Experiment 4 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TNFSF10 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | ||
| L-02 | CVCL_6926 | Ovarian cancer | Homo sapiens | |||
| 97H | Hepatocellular carcinoma | Homo sapiens | ||||
| Experimental
Result(s) |
The combination of As2O3 and sorafenib demonstrated potent anti-tumor activity in Huh7 and freshly-isolated HCC cells via a TRAIL-dependent pathway. | |||||
| Experiment 5 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | KG-1 | CVCL_0374 | Adult acute myeloid leukemia | Homo sapiens | ||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
The combination of sorafenib as a VEGF inhibitor with ATO synergistically inhibits cell proliferation and promotes apoptosis. | |||||
